Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [ZUOHXRkJx]
We spoke with Dr. Alex Andrews, CEO of Neurotech International (ASX:NTI), about the great data her company has recently received from a study of its NTI164 product in Autism Spectrum Disorders (ASX) and the potential of the upcoming Phase II/III trial. NTI164 is the first ever first full-spectrum medicinal cannabis product to be successfully studied in children with ASD.
Related Videos :
- Can cannabis ease chemotherapy side effects? [BQXVYAex9]
- Everything WRONG with THCa Products [2d8hgYkam]
- Best Wholesale CBD Gummies Oklahoma - CBD is Legal now - Best Wholesale CBD Gummies Oklahoma Pricing [yptXVmEdH]
- Smilz CBD Gummies Shark Tank [WD8bjDmVg]
- My Dogs Takes CBD | Product Review [zluINno8R]
Aired: December 3rd 2024
Buy Now:
Neurotech (ASX:NTI) has a product to reduce the symptoms for 93% of children with severe autism [ZUOHXRkJx]
Fixed iFrame
Responsive iFrame
Problems Playing Video? | Closed Captioning
